Huma

行业

植物保护, 生态与监测, 肥料与植物营养, 食品配料, 修复, 水务

主题

污水、水处理与生物修复

角色

生产商 — “…culture, turf, ornamentals, manufacturing additives, and soil and wastewater bioremediation. Benefits claimed…”

为何属于生物经济

Huma是一家员工持股公司，开发并生产腐植酸类生物刺激素、肥料和生物修复解决方案，应用于农业和环境领域。

发现途径

Sound Agriculture; [Rubric] United States · biostimulants

尚未被列为已评级方案的供应商。

子公司: Mesa Verde Humates® · Gro-Power, Inc.

• 2023-05 or earlier 最新状态: 公司由Bio Huma Netics, Inc.更名为Huma, Inc.。 ↗ ↗ ↗
• 2026-08-24 Humacyte Confirms Plans for ATEV Supplemental BLA Filing
  Humacyte says it plans to file a supplemental Biologic License Application with the FDA in November 2026 to add dialysis access as the second approved indication for its acellular tissue engineered vessel (ATEV), based on positive Phase 3 results (including …
• 2026-08-19 Humacyte Publishes V007 Phase 3 Trial Results - HUMA
  Humacyte announces publication of one-year results from the V007 Phase 3 trial of its acellular tissue engineered vessel (ATEV) for hemodialysis AV access in The Lancet Digital Health, showing superiority of ATEV over autogenous fistula, especially for women …
• 2026-08-21 Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
  Kahn Swick & Foti, LLC announced it continues an investigation into Humacyte, Inc. (HUMA) executives and directors over potential fiduciary and securities-law breaches related to disclosures around Humacyte’s FDA BLA review and a Form 483 FDA inspection, with …
• 2026-08-23 Humaans Expands Into US Payroll As It Accelerates US Growth | Markets Insider
  Humaans is expanding into the US payroll market, launching Humaans Payroll to integrate payroll with its existing workforce data, automation, and Athena AI platform, and rolling out to US customers this fall. This signals a strategic push to serve US-based and …
• 2026-04-25 Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
  Kahn Swick & Foti, LLC has initiated an investigation into Humacyte, Inc.’s officers and directors, focusing on potential fiduciary breaches and misconduct in connection with the company’s FDA BLA review process and related disclosures, including a Form 483 at …
• 2026-08-24 Humacyte Plans Supplemental BLA for ATEV - HUMA | BioPharmaWatch
  Humacyte plans to file a supplemental BLA with the FDA in November 2026 to add dialysis access as a second approved indication for its acellular tissue engineered vessel (ATEV), building on the December 2024 approval for vascular trauma and supported by …

股权与投资方 3

同类企业

Bio-Gro, Inc. · BioScientific, Inc. · Reforestation Technologies International · AgroLiquid · Corteva Biologicals · The Global Organics Group of Companies · The Espoma Company · CanGrow Crop Solutions Inc.